Bruker Corporation Intrinsic Value – Bruker microCT Expected to Lead Micro-CT Scanner Market to USD 1721231.5 Million By 2030
June 18, 2023
🌥️Trending News
Bruker Corporation ($NASDAQ:BRKR) is an American company that specializes in the production of advanced microscopy and analytical instruments for scientific research. With its Bruker microCT technology, the company is expected to be a major leader in the development of the Micro-CT Scanner Market, which is predicted to reach USD 1721231.5 Million by 2030. Bruker’s microCT technology produces high resolution 3D images which can be used for various materials analysis and medical imaging applications. Bruker Corporation has been a major player in the Micro-CT Scanner Market since its inception, competing with other major players such as North Star.
Bruker has continued to innovate and develop its microCT technology, pushing the boundaries of what the market can offer and enabling its customers to explore and analyze their materials in greater detail. With its high resolution 3D imaging capabilities, Bruker’s microCT technology is expected to lead the market in terms of innovation and growth over the next decade.
Share Price
On Tuesday, BRUKER CORPORATION shares opened at $71.7 and closed at $70.3, down 1.8% from the prior closing price of 71.6. BRUKER CORPORATION, one of the world’s leading providers of micro-CT scanners, is expected to be a major player in this market growth. The company’s focus on the development of innovative products and services to meet customer needs bodes well for its success in this competitive field. With its cutting-edge technology and reliable customer service, BRUKER CORPORATION is well positioned to take advantage of the opportunities made available by this growing market. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Bruker Corporation. More…
| Total Revenues | Net Income | Net Margin |
| 2.62k | 311.5 | 12.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Bruker Corporation. More…
| Operations | Investing | Financing |
| 284.1 | -258 | -228.6 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Bruker Corporation. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 3.76k | 2.55k | 7.58 |
Key Ratios Snapshot
Some of the financial key ratios for Bruker Corporation are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 8.8% | 21.4% | 17.4% |
| FCF Margin | ROE | ROA |
| 5.7% | 24.6% | 7.6% |
Analysis – Bruker Corporation Intrinsic Value
At GoodWhale, we did an in-depth analysis of BRUKER CORPORATION’s financial statements. After carefully assessing the company’s balance sheet, profitability, liquidity, and other financial metrics, we used our proprietary Valuation Line to determine the intrinsic value of BRUKER CORPORATION’s share at $73.7. Currently, BRUKER CORPORATION’s stock is traded at $70.3, meaning that it is undervalued by 4.6%. Thus, it may be a good option for investors looking to take advantage of the current market conditions. More…
Peers
Its products are used in a variety of applications, including drug discovery, food and environmental testing, and materials science research. The company’s main competitors are Tecan Group AG, Stevanato Group SPA, and Cerus Corporation.
– Tecan Group AG ($LTS:0QLN)
Tecan Group AG is a leading provider of laboratory instruments and solutions. The company has a market cap of 4.56B as of 2022 and a Return on Equity of 6.13%. Tecan provides a wide range of products and services for the life science research, diagnostics and pharmaceutical sectors. The company offers a broad range of solutions for drug discovery, genomics, diagnostics and forensics. Tecan also provides contract research services to the pharmaceutical industry.
– Stevanato Group SPA ($NYSE:STVN)
Stevanato Group SPA is a company that manufactures and sells pharmaceuticals and medical devices. The company has a market cap of 4.89B as of 2022 and a return on equity of 11.0%. The company’s products are sold in over 100 countries and it has a presence in Europe, North America, and Asia.
– Cerus Corp ($NASDAQ:CERS)
Cerus Corp is a medical technology company that specializes in blood safety. The company’s primary product is the Intercept Blood System, which is designed to inactivate viruses, bacteria, parasites, and other potentially harmful agents in donated blood. Cerus Corp’s market cap as of 2022 is 625.13M, and its ROE is -28.3%. The company has been facing some financial difficulties in recent years, but continues to invest in research and development in order to bring new products to market.
Summary
BRUKER Corporation (BRKR) is a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analysis. BRKR has been increasing its research and development investments in order to expand its product portfolio and market share. The company has concentrated its efforts on developing innovative technologies that can provide superior image resolution and accuracy, as well as greater productivity.
Additionally, BRKR has been focusing on investing in strategic partnerships and collaborations to increase its presence in the medical device market. Furthermore, the company’s portfolio of services and support is expected to drive growth over the forecast period. Overall, BRKR is well-positioned to capitalize on the growth in the global micro-CT scanner market.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
